CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced it has launched a new engineered stem cell line that will allow scientists to monitor the pluripotency of human embryonic stem cells (hESCs) without sacrificing those cells. The line is the first one with this characteristic to be made generally available for sale.
